Indications
Circulatory disorders in patients with: atherosclerosis, diabetes, Raynaud’s disease;
treatment of trophic ulcers, treatment of cerebral circulation disorders.
$43.00
Active ingredient: | |
---|---|
Dosage form: | |
Indications for use: | Atherosclerosis, Consequences of a stroke, Diabetic retinopathy, Disturbance of cerebral circulation, Frostbite, Raynaud's disease, Trophic ulcers, Vascular eye disease, Vascular lesions in diabetes mellitus |
Circulatory disorders in patients with: atherosclerosis, diabetes, Raynaud’s disease;
treatment of trophic ulcers, treatment of cerebral circulation disorders.
1 tablet contains:
Active substance:
pentoxifylline 600 mg;
Auxiliary substances:
hypromellose 15000 MPa * s,
microcrystalline cellulose,
crospovidone,
colloidal silicon dioxide,
magnesium stearate;
Shell composition:
macrogol 6000,
hypromellose 5 MPa * s,
anti-foaming agent SE2 MK silicon,
titanium dioxide,
talc,
polyacrylate dispersion 30%.
1 tablet contains:
Active ingredient:
pentoxifylline 600 mg;
Auxiliary substances:
hypromellose 15000 MPa * s,
microcrystalline cellulose,
crospovidone,
colloidal silicon dioxide,
magnesium stearate;
Shell composition:
macrogol 6000,
hypromellose 5 MPa * s,
anti-foaming agent SE2 MK silicon,
titanium dioxide,
talc,
polyacrylate dispersion 30%.
Pharmaceutical group:
vasodilating agent.
Pharmaceutical action:
Vasonite is a derivative of xanthine. Improves microcirculation in areas of impaired blood supply. Improves the rheological properties of blood (fluidity) by affecting the pathologically altered deformability of red blood cells, increases the elasticity of red blood cell membranes, inhibits the aggregation of red blood cells and platelets, and reduces the increased blood viscosity.
The mechanism of action of the drug is associated with the inhibition of phosphodiesterase and the accumulation of cAMP in vascular smooth muscle cells and in blood cells. Pentoxifylline inhibits the aggregation of platelets and red blood cells, reduces the level of fibrinogen in blood plasma and increases fibrinolysis, which leads to a decrease in blood viscosity and an improvement in its rheological properties.
Improves the supply of oxygen to tissues in areas of impaired blood circulation (including in the extremities, central nervous system, and to a lesser extent – in the kidneys). With occlusive damage to the peripheral arteries (intermittent claudication), it leads to an increase in walking distance, elimination of night cramps, calf muscles, and reduction of pain at rest.
When the cerebral circulation is disturbed, it improves symptoms. It has a weak myotropic vasodilating effect, slightly reduces OPSS and slightly dilates the coronary vessels.
Circulatory disorders in patients with: atherosclerosis, diabetes, Raynaud’s disease;
treatment of trophic ulcers, treatment of cerebral circulation disorders.
Application of the drug Vasonitis during pregnancy is contraindicated.
If it is necessary to use the drug during lactation, stop breastfeeding.
From the digestive system: possibly – nausea, vomiting, diarrhea, dry mouth, decreased appetite, feeling of fullness in the abdomen, epigastric pain, increased activity of liver enzymes (ALT, AST, LDH) and alkaline phosphatase, cholecystitis, hepatitis, jaundice; rarely-unpleasant taste in the mouth, hypersalivation.
From the central nervous system: relatively rare – headache, dizziness, restlessness, sleep disturbances, seizures.
From the side of the senses: rarely-conjunctivitis, scotoma, blurred vision, ear pain.
From the cardiovascular system: when using the drug in high doses, it is possible to reduce blood pressure, tachycardia, angina pectoris, cardiac arrhythmias, hyperemia of the facial skin, ” flushes ” of blood to the skin of the face and upper chest, edema.
Allergic reactions: possibly-pruritus, skin rash, urticaria, angioedema; rarely-anaphylactic shock.
Hematopoietic and hemostatic disorders: rarely-bleeding (from the vessels of the stomach, intestines, skin and mucous membranes), thrombocytopenia, leukopenia, pancytopenia, hypofibrinogenemia, changes in the picture of peripheral blood, aplastic anemia. In this regard, it is necessary to conduct regular monitoring of the blood picture.
Other services: rarely – malaise, increased fragility of nails, changes in body weight, nasal congestion.
Pentoxifylline can enhance the effect of drugs that affect the blood coagulation system (indirect and direct anticoagulants, thrombolytics), anitibiotics (including cephalosporins-cefamandol, cefaperazone, cefotetane), valproic acid.
Increases the effectiveness of antihypertensive drugs, insulin and oral hypoglycemic drugs. Cimetidine increases the concentration of pentoxifylline in plasma (risk of side effects).
Co-use with other xanthines may lead to excessive nervous excitement in patients.
Tablets covered with an enteric coating are swallowed whole, washed down with a small amount of water.
The daily dose is divided into 3 doses. The initial dose is 600 mg / day.
As the condition improves, the dose can be reduced to 300 mg / day.
Prolonged dosage forms are prescribed 2-3 times a day.
Symptoms: nausea, dizziness, decreased blood pressure, increased body temperature (chills), tachycardia, drowsiness or agitation, loss of consciousness, areflexia, possible tonic-clonic convulsions, vomiting like “coffee grounds” (as a sign of gastrointestinal bleeding), arrhythmias.
Treatment: gastric lavage, then carry out symptomatic therapy. There is no specific antidote. In case of vomiting with traces of blood, gastric lavage is unacceptable.
Treatment should be carried out under the control of blood pressure. In patients with diabetes mellitus taking hypoglycemic drugs, use in large doses may cause severe hypoglycemia (dose adjustment is required).
When prescribed simultaneously with anticoagulants, it is necessary to carefully monitor the parameters of the blood coagulation system. In patients who have recently undergone surgery, systematic monitoring of Hb and hematocrit is necessary.
The administered dose should be reduced in patients with low and unstable blood pressure. In the elderly, it may be necessary to reduce the dose (increase bioavailability and decrease the rate of elimination).
The safety and efficacy of pentoxifylline in children are poorly understood. Tobacco smoke can reduce the therapeutic effectiveness of the drug. Compatibility of the pentoxifylline solution with the infusion solution should be checked on a case-by-case basis.
Vasonit tablets of prolonged action, film-coated white, oblong, biconvex, with a risk on both sides.
In a dark place, at a temperature not exceeding 25 °C
5 years
Pentoxifylline
By prescription
long-acting tablets
For adults as directed by your doctor
Atherosclerosis, Diabetic retinopathy, Vascular lesions in diabetes mellitus, Consequences of stroke, Frostbite, Vascular diseases of the eyes, Trophic ulcers, Cerebral circulation disorders, Raynaud ‘s disease
Reviews
There are no reviews yet